Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Daily aspirin might cut risk of fibrosis progression

Key clinical point: Daily aspirin use was associated with a significantly lower risk for new-onset and advanced fibrosis.

Major finding: Daily aspirin users had significantly lower risk for developing incident advanced fibrosis compared with nonregular users (adjusted hazard ratio, 0.63; 95% CI, 0.43-0.85).

Study details: Prospective cohort study of 361 adults with biopsy-confirmed nonalcoholic fatty liver disease.

Disclosures: Funders included the National Institutes of Health and the AASLD Foundation. The investigators reported having no conflicts of interest.

Citation:

Simon TG et al. Clin Gastroenterol Hepatol. 2019 May 8.